Vicky brings more than 25 years of biopharmaceutical business development and corporate strategy experience to the Board as the Company advances its clinical and preclinical programs and expands its partnering activity. The appointment comes at an important stage as Continuity Biosciences moves from platform development into clinical execution. Vicky joins the Board with direct experience structuring the licensing and corporate development transactions, closely aligning with Continuity’s expanding strategic partnering activities.
